Dr. Doriano Fabbro is a Senior VP of Cellestia Biotech. He obtained his PhD from the University of Basel and has been a successful leader and drug discoverer with over 30 years experience in the pharmaceutical industry. Dr. Fabbro was the Head of Oncology Drug Discovery and the Kinase Platform at Novartis, and has overseen...
Dr. ShiYin Foo brings 20 years of experience as a practicing physician and a catalyst in advancing innovative new programs through the various stages of drug development. She has expertise in a breadth of disease areas, including cardiorenal, immunology/ inflammation and rare diseases, as well as an interest in novel and adaptive clinical trial designs....
Graduated as MD in 1970 from Liège University (Belgium), Dr. Guy Heynen is an Internal Medicine specialist with experience in immunology and rheumatology. He has extensive experience in clinical development, trial design, and strategic and translational evaluations. Dr. Heynen joined Pfizer International as International Medical Director in 1982, with assignments in Brussels, New York, and...
Dr. Hiroshi Nagabukuro is the Co-Founder and CEO of both ARTham Therapeutics and JURO SCIENCES. ARTham was recently acquired by Kaken Pharmaceutical for $100M, and JURO was founded as a spin-out of ARTham. He has extensive drug discovery experience for over 25 years across multiple therapeutic areas. Before ARTham, Dr. Nagabukuro was a senior director...
Dr. Dean Rigel is a senior drug discovery scientist, in vivo pharmacologist/physiologist, and bioengineer with over 30 years of pharmaceutical and instrumentation/device experience. He obtained a PhD in Biomedical Engineering from Case Western Reserve University, joined Novartis and made significant contributions to enable 11 compounds to enter human clinical trials; some, including LCZ696/Entresto® and LCI699/Isturisa®,...
Akiyoshi Fujiuchi is responsible for efficacy pharmacology and preclinical research in PRISM BioLab. He has about 30 years of deep knowledge and experience in drug discovery, especially in vivo animal experiments, at RaQualia Pharma as well as Pfizer. He nominated development candidates from internal and external collaborative projects as a lead. He received his BS...
Michihiro Maeda joined PRISM BioLab as CFO / Corporate Director. After obtaining an Economics degree at Austin College, TX, he took on various Finance responsibilities including M&A / IR / operational turnaround at USEN, CFO at Abbott Japan and Finance lead at Aillis Inc., as well as IPO / Fund raising lead at Promethera Biosciences...
Yohei Matsuda is responsible for medicinal chemistry and technology platform development. Before joining PRISM BioLab, he worked as a medicinal chemist at Taisho Pharmaceutical Co., Ltd. and engaged in drug discovery research in various disease areas and drug discovery technology development. He was involved in many projects as a chemistry leader and contributed to the...
Takeshi Matsushita is responsible for medicinal chemistry at PRISM BioLab. He started his career as a medicinal chemist at ONO Pharmaceutical Co., Ltd., where he experienced a wide range of drug discovery programs including GPCRs and kinases, and contributed to the discovery of several clinical candidates with disease areas including CNS. Prior to joining to...
Hiroyuki Ohshiro is responsible for in vitro pharmacology, MOA analysis, and new research projects. He has more than 20 years of experience in drug discovery research. Prior to joining PRISM BioLab, he was at RaQualia Phama and led as biology and manager many discovery projects. Hiroyuki worked at Pfizer R&D Japan, he contributed in many...
English 
Japanese 
